A Study to Evaluate the Safety of H1N1 Monovalent Vaccine (MEDI3414) in Healthy Adults
Condition: Healthy
Intervention: MEDI3414 [Influenza A/H1N1 live attenuated, intranasal]; Placebo
Intervention description: 0.5 mL; (intranasal sprayer); (intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer)
Phase: Phase 4
Study type: Interventional
Primary purpose: Prevention
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Enrollment: 300.0
Sex: All
Minimum age: 18 Years
Maximum age: 49 Years
Healthy volunteers: Accepts Healthy Volunteers

Summary:

      The purpose of this study was to determine the safety and descriptive immunogenicity of the
      H1N1 influenza vaccine in healthy adults.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Male or female, 18 to 49 years of age (not yet reached their 50th birthday) at the
             time of randomization

          -  Healthy by medical history and physical examination

          -  Written informed consent and any locally required authorization (eg, Health Insurance
             Portability and Accountability Act [HIPAA] in the United States of America [USA],
             European Union [EU] Data Privacy Directive in the EU) obtained from the subject/legal
             representative prior to performing any protocol-related procedures, including
             screening evaluations

          -  Females of childbearing potential, (ie, unless surgically sterile [eg, bilateral tubal
             ligation, bilateral oophorectomy, or hysterectomy], has sterile male partner, is at
             least 1 year post menopause, or practices abstinence) must use an effective method of
             avoiding pregnancy (including oral, transdermal, or implanted contraceptives,
             intrauterine device, female condom with spermicide, diaphragm with spermicide,
             cervical cap, or use of a condom with spermicide by the sexual partner) for 30 days
             prior to the first dose of investigational product, and must agree to continue using
             such precautions for 60 days after the second dose of investigational product. In
             addition, the subject must also have a negative urine or blood pregnancy test at
             screening and, if screening and Day 1 do not occur on the same day, on the day of
             vaccination prior to randomization.

          -  Males, unless not sexually active, must use an effective method of birth control with
             a female partner and must agree to continue using such contraceptive precautions for
             at least 30 days after the second dose of investigational product (from Day 1 through
             Day 59 of the study)

          -  Subject is available by telephone

          -  Subject is able to understand and comply with the requirements of the protocol, as
             judged by the investigator

          -  Subject is able to complete follow-up period of 180 days after Dose 2 as required by
             the protocol

        Exclusion Criteria:

          -  History of hypersensitivity to any component of the investigational product including
             egg or egg protein, gelatin or arginine, or serious, life-threatening, or severe
             reactions to previous influenza vaccinations

          -  History of hypersensitivity to gentamicin

          -  Any condition for which the inactivated influenza vaccine is indicated, including
             chronic disorders of the pulmonary or cardiovascular systems (eg, asthma), chronic
             metabolic diseases (eg, diabetes mellitus), renal dysfunction, or hemoglobinopathies
             that required regular medical follow-up or hospitalization during the preceding year

          -  Acute febrile (> 100.0°F oral or equivalent) and/or clinically significant respiratory
             illness (eg, cough or sore throat) within 14 days prior to randomization

          -  History of asthma

          -  Any known immunosuppressive condition or immune deficiency disease, including human
             immunodeficiency virus infection, or ongoing immunosuppressive therapy

          -  History of Guillain-Barré syndrome

          -  A household contact who is severely immunocompromised (eg, hematopoietic stem cell
             transplant recipient, during those periods in which the immunocompromised individual
             requires care in a protective environment); subject should additionally avoid close
             contact with severely immunocompromised individuals for at least 21 days after receipt
             of investigational product

          -  Receipt of any investigational agent within 30 days prior to randomization, or
             expected receipt through 30 days after the second dose of investigational product (use
             of licensed agents for indications not listed in the package insert is permitted)

          -  Expected receipt of antipyretic or analgesic medication on a daily or every other day
             basis from randomization through 14 days after receipt of each dose of investigational
             product

          -  Administration of intranasal medications within 14 days prior to randomization, or
             expected receipt through 14 days after administration of each dose of investigational
             product

          -  Receipt of any nonstudy vaccine within 30 days before or after Dose 1 or expected
             receipt of any nonstudy vaccine within 30 days before or after Dose 2

          -  Known or suspected mitochondrial encephalomyopathy

          -  Subject is pregnant or a nursing mother

          -  Any condition (eg, chronic cough, allergic rhinitis) that, in the opinion of the
             investigator, would interfere with evaluation of the investigational product or
             interpretation of subject safety or study results

          -  Subject or immediate family member of subject is an employee of the clinical study
             site or is otherwise in involved with the conduct of the study